Related Experiment Video

Updated: Jul 5, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia

John E Paes1, Matthew D Ringel

  • 1Division of Endocrinology, The Ohio State University Medical Center, The Ohio State University, 1581 Dodd Drive, 4th Floor, McCampbell Hall, Columbus, OH 43210, USA.

Endocrinology and Metabolism Clinics of North America
|May 27, 2008
PubMed

Insights

The phosphatidylinositol 3-kinase (PI3K) pathway is crucial in thyroid cancer. Its overactivation, often due to PTEN loss or PIK3CA mutations, drives follicular neoplasia and anaplastic thyroid cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • The phosphatidylinositol 3-kinase (PI3K) pathway regulates critical cellular processes like apoptosis, proliferation, and motility.
  • Aberrant PI3K pathway activation is implicated in various cancers.
  • Specific genetic alterations, including PTEN inactivation and PIK3CA mutations, are linked to thyroid neoplasia.

Purpose of the Study:

  • To discuss the role of PI3K pathway activation in thyroid cancer.
  • To highlight recent advancements in understanding PI3K signaling in thyroid malignancies.

Main Methods:

  • Literature review focusing on PI3K pathway.
  • Analysis of genetic abnormalities in thyroid cancer.
  • Review of recent research on PI3K signaling.

Main Results:

  • Enhanced PI3K pathway activation is a common feature in thyroid cancers.
  • PTEN inactivation and PIK3CA mutations are key drivers of PI3K pathway activation in thyroid neoplasia.
  • These alterations are particularly prevalent in follicular thyroid neoplasia and anaplastic thyroid cancer.

Conclusions:

  • PI3K pathway dysregulation plays a significant role in the pathogenesis of thyroid cancer.
  • Understanding these mechanisms offers potential therapeutic targets for thyroid malignancies.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and produces two-second...